ATM programs let companies drip-feed shares into the market over time, meaning dilution pressure won't hit all at once but will act as a persistent overhang on the stock. For existing shareholders, the $60mn program represents a concrete downside catalyst that didn't exist when the article went live. Management is effectively agreeing that shares are richly priced by tapping equity markets rather than waiting for fundamentals to catch up.
Watch the pace of ATM drawdowns in upcoming quarterly filings. Rapid selling would signal urgency; a slow drip suggests opportunistic hedging. Either way, the dilution math now works against the bull case.
Aehr Test Systems Stock Soars 59% on AI Backlog — Now It Trades at 520 Times Earnings
NEW YORK, April 10 —
Aehr Test Systems (AEHR) jumped 59.5% to all-time highs after reporting a surge in AI-driven backlog in Q3 FY2026.
- Shares hit $68.86, up 59.5%, on forward demand signals from AI semiconductor test customers
- The stock now trades at 519.7x forward earnings on $45mn in trailing twelve-month revenue
- Q4 FY2026 is the test: backlog must convert to actual revenue, while a new $60mn ATM offering adds dilution risk
What Actually Happened
Quarterly revenue was weak. Most of the celebratory coverage glosses over that. What lit the fuse was backlog: AI chip customers need burn-in and test capacity before they ship. Aehr's order book swelled enough to convince the market that revenue is a timing issue, not a demand issue.
This is a company with $45mn in TTM revenue trading like it already has multiples of that locked in. The bet is simple. As AI chip production scales, every chip needs testing. Aehr sells the machines that do it. The backlog surge says customers are placing orders now for capacity they'll need in coming quarters.
The company sees the moment too. Alongside earnings, Aehr established a $60mn at-the-market equity offering program. When a ~$2bn market cap company sets up a facility to sell that much stock, it signals two things: management wants capital for growth, and management thinks the stock price is rich enough to sell into.
The Catch
A 520x forward P/E is not a valuation. It's a bet on faith. At $45mn in TTM revenue, Aehr needs to triple or quadruple sales just to reach a P/E ratio growth investors would call "expensive" instead of "absurd." Backlog is not revenue. Orders can be delayed, reduced, or cancelled.
Then there's the ATM. A $60mn offering program doesn't mean they'll sell $60mn in stock tomorrow. But it does mean every rally from here comes with a seller who has a legal obligation to maximize proceeds. That's a ceiling that drops the longer the stock stays elevated. For a stock that just moved 59.5% in a day, the supply overhang is real.
Bottom Line
Aehr is a legitimate AI infrastructure play in a niche most investors ignore: testing equipment that sits between chip fabrication and deployment. The demand story is credible. The price is not. At 520x forward earnings, you're paying today for revenue that might arrive in 2027 or 2028 — while the company has set up a mechanism to dilute you along the way.
This is a name to track, not chase. The number that matters is Q4 FY2026 revenue. If backlog converts, the story holds. If it doesn't, 520x is a long way to fall.
Aehr Test Systems doesn't have a Basis Report yet. Generate your free AEHR investment report here for a full breakdown of the financials.
Basis Report does not hold positions in securities discussed. This is not investment advice.